The Need for Societal Investment to Improve Cervical Cancer Outcomes in Nigeria: A commentary

Jonah Musa


Although cervical cancer is a preventable cancer with a well-known natural history, it remains a huge burden in developing countries of sub-Saharan Africa where organized cervical cancer screening services are lacking. Developed countries that have invested on providing organized screening programs have made substantial progress in reducing both incidence and mortality due to cervical cancer. Implementing evidence-based interventions such as human papillomavirus (HPV) vaccination of young girls, early detection and treatment of premalignant conditions of the cervix through conventional Pap cytology, HPV screening or visual aided inspection with acetic acid could significantly reduce incidence of new cases at population level. Societal investment for such preventive services and provision of effective treatment for those diagnosed at early stages will yield economic benefits in reducing premature deaths of women at the prime of their productive lives. From a societal perspective, this should be a priority area for national investment towards the achievement of sustainable development in Nigeria and similar settings in Africa. (Afr J Reprod Health 2017; 21[4]: 17-23).

Full Text:



International Agency for Research on Cancer/World

Health Organization press release (2013). Latest world cancer statistics. Global cancer burden rises to 14 . 1 million new cases in 2012 : Marked increase in breast cancers must be addressed. 2013. Available at:

Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano

R, Lopez AD, Murray CJL and Mohsen Naghavi. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011 Oct 22;378(9801):1461–84.

Awolude O, Morhason-Bello IO, Denny L and Adewole

IF. Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention. Vaccine. 2013;31 Suppl 5:vii–x.

Ekwueme DU, Uzunangelov VJ, Hoerger TJ, Miller JW,

Saraiya M, Benard VB, Hall IJ, Royalty J, Li C and Myers ER. Impact of the National Breast and Cervical Cancer Early Detection Program on Cervical Cancer Mortality Among Uninsured Low-Income Women in the U.S., 1991–2007. Am J Prev Med. 2014;47(3):300–8.

Ekwueme DU, Subramanian S, Trogdon JG, Miller JW,

Royalty JE, Li C, Guy GP Jr., Crouse W, Thompson H and Gardner JG. Cost of services provided by the National Breast and Cervical Cancer Early Detection Program. Cancer. 2014;120(16):2604–11.

Trogdon JG, Ekwueme DU, Subramanian S and Crouse

W. Economies of scale in federally-funded state-organized public health programs: results from the National Breast and Cervical Cancer Early Detection Programs. Health Care Manag Sci. 2013;17(4):321–30.

GLOBAL REPORT. United Nations Programme on HIV

and AIDS (UNAIDS); 2013. Available from:

Denslow SA, Rositch AF, Firnhaber C, Ting J and Smith

J. Incidence and Progression of Cervical lesions in Women with HIV: a Systematic Global Review. Int J STD AIDS. 2014; 25(3):163–77.

Mogtomo MLK, Malieugoue LCG, Djiepgang C,

Wankam M, Moune A and Ngane AN. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agent Cancer. 2009;4:9.

Castellsagué X. Natural history and epidemiology of

HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3):S4-7.

Musa J, Nankat J, Achenbach CJ, Shambe IH, Taiwo BO,

Mandong B, Daru PH, Murphy RL and Sagay AS. Cervical cancer survival in a resource-limited setting-North Central Nigeria. Infectious Agents and Cancer; 2016;11(1):15.

Ewelukwa O, Onoka C and Onwujekwe O. Viewing

health expenditures, payment and coping mechanisms with an equity lens in Nigeria. BMC Health Serv Res. 2013 ;13(1):87.

Brookfield KF, Cheung MC, Lucci J, Fleming LE and

Koniaris LG. Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer. 2009; 115 (1): 166–78.

Gunderson CC, Nugent EK, Mcmeekin DS and Moore

KN. Distance Traveled for Treatment of Cervical Cancer Who Travels the Farthest , and Does it Impact Outcome ? Int J Gynecol Cancer 2013;23(6):1099–103.

Onwujekwe O, Hanson K, Ichoku H and Uzochukwu B.

Financing incidence analysis of household out- of-pocket spending for healthcare : getting more health for money in Nigeria ? Int J Health Plann Manage. 2014:174–85.

Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL,

Sun CC and Ramondetta LM. Social Factors Affecting Treatment of Cervical Ethical Issues and Policy Implications. Obstet Gynecol 2008;111(3):747–51.

Subramanian S, Trogdon J, Ekwueme DU, Gardner JG,

Whitmire JT and Rao C. Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care. Womens Health Issues. 2010;20(6):400–5.

WHO. WHO guidelines for screening and treatment of

precancerous lesions for cervical cancer prevention. 2013;

Bosch FX, Lorincz A, Muñoz N, Meijer CJLM and

Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.

Campos NG, Burger EA, Sy S, Sharma M, Schiffman M,

Rodriguez AC, Hildesheim A, Herrero R and Kim JJ. An Updated Natural History Model of Cervical Cancer : Derivation of Model Parameters. Am J Epidemiol 2014;180(5):545–55.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow

SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M and Dubin G. For the HPV PATRICIA Study Group. Efficacy of human papillomavirus ( HPV ) -16 / 18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types ( PATRICIA ): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374 (9686): 301–14. Erratum in: Lancet. 2010 Sep 25; 376 (9746):1054.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U,

Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G. For the HPV PATRICIA Study Group. Overall efficacy of HPV-16 / 18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13 (1): 89–99. Erratum in: Lancet Oncol. 2012 Jan; 13(1):e1.

Kriekinge G Van, Castellsagué X, Cibula D and

Demarteau N. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014;32(6):733–9.

Demarteau N, Morhason-Bello IO, Akinwunmi B and

Adewole IF. Modeling optimal cervical cancer prevention strategies in Nigeria. BMC Cancer. 2014;14(1):365.

Schiffman M and Wacholder S. Success of HPV

vaccination is now a matter of coverage. Lancet Oncol. 2012;13(1):10–2.

Benard VB, Royalty J, Saraiya M, Rockwell T and Helsel

W. The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women. Cancer Causes Control. 2015; 26 (5): 713–9.

Sankaranarayanan R, Nene BM, Shastri SS, Jayant K,

Muwonge R, Budurkh AM, Hingmire S, Malvi SG, Thorat R, Kothari A Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N and Dinshaw KA. HPV Screening for Cervical Cancer in Rural India. N Engl J Med. 2009;360(14):1385–94.

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman D M, Kenter GG, Cuzick J, Snijders PJ and Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders

PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJLM, and the International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer : follow-up of four European randomised controlled trials. Lancet. 2014;383 (9916): 524-32.

Arbyn M, Buntinx F, Ranst M V, Paraskevaidis E,

Martin-Hirsch P and Dillner J. Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia. J Natl Cancer Inst. 2004; 96(4):280–93.

Goldhaber-Fiebert JD, Stout NK, Salomon J, Kuntz KM

and Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308–20.

Jin XW, Lipold L, Foucher J, Sikon A, Brainard J,

Belinson J, Schramm S, Nottingham K, Hu B and Rothberg MB. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years. J Gen Intern Med. 2016;31(11):1338–44.

Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J and

Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet. 2005; 89 (2):S4–12.

Mvundura M and Tsu V. Estimating the costs of cervical

cancer screening in high-burden Sub-Saharan African countries. Int J Gynecol Obstet. 2014;126(2):151–5.

Quentin W, Adu-sarkodie Y, Terris-prestholt F, Legood

R and Opoku BK. Costs of cervical cancer screening and treatment using visual inspection with acetic acid ( VIA ) and cryotherapy in Ghana : the importance of scale.Trop Med Int Health. 2011;16(3):379–89.

Backes FJ and Fowler JM. Hysterectomy for the

Treatment of Gynecologic Malignancy. Clin Obstet Gynecol 2014;57(1):115–27.

Katanyoo K, Praditsitthikorn N, Tangjitgamol S and

Manusirivithaya S. Cost-utility analysis of treatments for stage IB cervical cancer. J Gynecol Oncol. 2014;25(2):97–104.


  • There are currently no refbacks.